ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1294

A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis

Melvin A. Churchill1, Luis F. Flores-Suarez2, Daniel J. Wallace3, Kristine Phillips4, Richard W. Martin5, Mario H. Cardiel6, Jeffrey Kaine7, Edgar Bautista8, David H. Salinger9, Erin Stevens9, Christopher B. Russell9 and David A. Martin9, 1Arthritis Center of Nebraska, Lincoln, NE, 2Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 5Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, 6Research Unit, Hospital, Morelia, Mexico, 7Sarasota Arthritis Research Center, Sarasota, FL, 8Medical Sciences, Amgen, Thousand Oaks, CA, 9Medical Sciences, Amgen, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose:   The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA).  Brodalumab is a human, immunoglobulin G2 (IgG2) monoclonal antibody that binds with high affinity to human IL 17RA and blocks the biological activity of IL 17A, IL-17F, IL-17A/F heterodimers, and IL-25.  Increased levels of IL-17A have been detected in the synovial fluid of patients with RA and furthermore, blockade of IL-17A signaling can inhibit osteoclast formation induced by culture media of RA synovial tissues.  The aim of this study was to evaluate safety, pharmacokinetics, and preliminary efficacy of brodalumab in subjects with moderate to severe RA.

Methods:   This phase Ib, randomized, placebo-controlled, double-blind multiple ascending dose study enrolled subjects with a moderate to severe RA (>6/66 swollen and >8/68 tender joints).  Subjects were randomized 3:1 to receive multiple doses of brodalumab (50mg, 140mg or 210mg subcutaneously every two weeks for 6 doses, or 420mg or 700mg intravenously every 4 weeks for two doses) or placebo.  The primary endpoint was safety and tolerability of brodalumab,  including incidence of adverse events (AEs).  Multiple dose pharmacokinetics was a secondary endpoint.  Exploratory endpoints included pharmacodynamics, and improvements in RA clinical metrics.  Assessments were performed up to end of study on day 127.

Results:   40 subjects were randomized and received at least one dose; there was one dropout on day 85 due to worsening RA (placebo).  Treatment with brodalumab resulted in receptor occupancy by brodalumab on circulating leukocytes and inhibition of IL-17 receptor signaling.  Dose-dependent increases in the magnitude and duration of mean receptor occupancy were observed.  Treatment-related AEs were reported by 3 (30.0%) of 10 placebo subjects and 7 (23.0%) of 30 brodalumab subjects.  The most common treatment-related adverse event was headache (20%) for placebo subjects and leukocytosis (7%) for brodalumab subjects. Serious AEs occurred in 2 subjects during the study [complicated migraine (placebo) and non-cardiac chest pain (brodalumab, 420 mg IV)]; neither was considered by the investigator related to investigational product.  On day 85 (week 13) ACR20 was achieved by 11 (36.7%) of 30 subjects receiving brodalumab and 2 (22.0%) of 9 subjects receiving placebo. Few ACR50 or ACR70 responses were observed in either active or placebo group at day 85.

Conclusion:   This small ascending dose phase 1b study demonstrates that multiple dose administration of brodalumab was tolerated in subjects with active RA.  Conclusions about efficacy cannot be reached given the study design.


Disclosure:

M. A. Churchill,

Amgen,

8;

L. F. Flores-Suarez,
None;

D. J. Wallace,

Amgen,

5;

K. Phillips,
None;

R. W. Martin,

Amgen,

9,

Lilly,

9,

Pfizer Inc,

9;

M. H. Cardiel,
None;

J. Kaine,

Amgen,

8;

E. Bautista,

Amgen,

3;

D. H. Salinger,

Amgen,

3;

E. Stevens,

Amgen,

3;

C. B. Russell,

Amgen,

3;

D. A. Martin,

Amgen,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-ib-multiple-ascending-dose-study-evaluating-safety-pharmacokinetics-and-early-clinical-response-of-brodalumab-amg-827-a-human-anti-interleukin-17-receptor-il-17r-antibody-in-rheum/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology